NCT05252715View on ClinicalTrials.gov

Immunogenicity and Safety of Meningococcal ACYW135 Polysaccharide Conjugate Vaccine in Volunteers Aged From 3 to 5 Months

PHASE3Active, not recruitingINTERVENTIONAL
Enrollment

1,200

Participants

Timeline

Start Date

December 18, 2021

Primary Completion Date

August 22, 2023

Study Completion Date

September 18, 2024

Conditions
Meningitis, Meningococcal
Interventions
BIOLOGICAL

Meningococcal ACYW135 Polysaccharide Conjugate Vaccine

Single intramuscular dose contains 5 µg each of Serogroup A, C, Y, and W135 meningococcal polysaccharide combined with tetanus toxoid.

BIOLOGICAL

Meningococcal A and C Polysaccharide Conjugate Vaccine

Single intramuscular dose contains 10 µg each of Serogroup A and C meningococcal polysaccharide combined with tetanus toxoid.

Trial Locations (2)

Unknown

Liujiang Center for Disease Control and Prevention, Liuzhou

Binyang Center for Disease Control and Prevention, Nanning

All Listed Sponsors
lead

Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd

INDUSTRY